Abstract
Background Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are a novel antidiabetic class that inhibits glucose reabsorption and produce glycosuria. These medications are being increasingly used as dual therapy with metformin for type 2 diabetes (T2D) treatment, due to their beneficial effect on weight and blood pressure. Three agents are approved for clinical use and they may differ on potency due to inhibition of only renal or both renal and bowel glucose transportation.
Highlights
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are a novel antidiabetic class that inhibits glucose reabsorption and produce glycosuria
Materials and methods MEDLINE, Cochrane central and EMBASE databases were searched for randomized clinical trials (RCTs) including patients with type 2 diabetes (T2D) allocated to SGLT2i for at least 12 weeks
CANA 300 mg, EMPA 25 mg and DAPA 10 mg were associated with better g.lycemic control (HbA1c -1.01%, -0.69%, -0.51%, respectively), and weight loss (-2.66 kg; -1.81 kg; -1.80 kg, respectively) when compared to placebo
Summary
Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Lana Catani Pinto, Dimitris Varvaki Rados, Luciana Reck Remonti*, Caroline Kaercher Kramer, Cristiane Bauermann Leitao, Jorge Luiz Gross. From 20th Brazilian Diabetes Society Congress Porto Alegre, Brazil. From 20th Brazilian Diabetes Society Congress Porto Alegre, Brazil. 11-18 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
